Targeting CLK2 in combination with PARP inhibitor is synergistic in inducing more severe DNA damage in cisplatin‐resistant OC cells, attenuating tumor growth, and prolonging survival time in mice bearing patient‐derived xenografts (PDXs). Here, CLK2 is linked to neoplasm.